The world’s first patient to successfully receive a CRISPR gene-editing treatment was discharged from Children’s Hospital of Philadelphia on June 2, ABC News reported.
KJ Muldoon, a 10-month-old who was born with severe carbamoyl phosphate synthetase 1 deficiency, received the first infusion of the bespoke therapy in February. CHOP and Philadelphia-based Penn Medicine collaborated on his treatment, and he responded well to follow-up doses in March and April, his clinicians said.
The rare metabolic disease disrupts the body’s urea cycle, which is the breakdown and removal of nitrogen, and usually results in death within the first few months of life.
He quickly reached a weight appropriate for his developmental stage and “graduated” from the hospital in a blue cap and gown, ABC News reported.
“While KJ will need to be monitored carefully for the rest of his life, our initial findings are quite promising,” Rebecca Ahrens-Nicklas, MD, PhD, director of CHOP’s gene therapy for inherited metabolic disorders frontier program, said in a May statement.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.